Skip to content

Efficacy of WARTNER anti-wart local drug on genital warts

A parallel, self-controlled clinical trial to determine the healing effect of WARTNER in male patients with genital wart

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT138811073200N1
Enrollment
20
Registered
2015-04-11
Start date
2015-04-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genital wart. Anogenital (venereal) warts

Interventions

Intervention 1: Control lesion: no intervention. Intervention 2: Intervention lesion: according to instruction, applicator is placed in sponge section. Then aerocele can is contacted to applicator and
Treatment - Drugs
Control lesion: no intervention
Intervention lesion: according to instruction, applicator is placed in sponge section. Then aerocele can is contacted to applicator and sponge is cryoliquid polluted. After waiting for 20 seconds, ap

Sponsors

Manoosha-Daru
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 139 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Male sex, >= 18 years old of age, at least 2 genital wart lesion approved by dermatologist, consent to participate and being followed for visits, consent to discontinue the other anti-genital wart drugs Exclusion criteria: diagnosed case of diabetes mellitus, Drug addiction, Other STDs, HIV positive, other immunodeficiency diseases, active skin lesion in genital ares, serious adverse event or intolerance to previous cryotherapy , cold sensitivity history, any tattoo, scar or pigmentation in the field of intervention which could affect the evaluation of the site, Being in the waiting list or participation in another cryotherpy trial at the same time of our study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Intervention and control lesion size. Timepoint: Days 0 and 14. Method of measurement: Caliper and Camera.

Secondary

MeasureTime frame
Clearance of lesion. Timepoint: Day 14. Method of measurement: Observation and photography.;Adverse event. Timepoint: 2 weeks after intervention. Method of measurement: Patient information.;Lesion recurrence. Timepoint: 6 weeks after intervention. Method of measurement: observation.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Firooz

Center For Research And Training In Skin Diseases And Leprosy

FIROZALI@TUMS.AC.IR+98 88972220

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026